Recurrent Lymphoepithelioma of the Nasopharynx Completed Phase 1 Trials for Cetuximab (DB00002)

IndicationStatusPhase
DBCOND0029500 (Recurrent Lymphoepithelioma of the Nasopharynx)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00397384Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerTreatment
NCT01637194Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck CancerTreatment